This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Amgen files reply for judgment in Regeneron's US antitrust case over cholesterol drug

( July 11, 2025, 15:57 GMT | Official Statement) -- MLex Summary: Amgen filed a reply in support of its motion for a judgment in its favor after a jury awarded Regeneron damages in an antitrust suit over cholesterol-reducing medication, saying the opposition ignores the case law, dodges Amgen’s arguments, and summarily asserts that the court should defer to the jury. It argued that Regeneron failed to present sufficient evidence to support the assumption that, absent the alleged anticompetitive conduct, Regeneron would have secured exclusive coverage at CVS with a much lower rebate.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections